Dividend investing is back in the spotlight for 2026, and I've got my eye on two giants: Lloyds and GSK. These companies are not just big names but also steady dividend payers, making them an intriguing prospect for income-focused investors.
Lloyds: A Steady Performer with Risks
Lloyds has had an impressive year, with its shares soaring to around 100p as of my writing on January 9th, following a whopping 85.5% gain in the last 12 months. The higher interest rates have been a boon for the company, boosting its earnings from loans and allowing it to share the wealth with investors.
But here's where it gets controversial: despite the strong performance, Lloyds faces some clear risks. Its heavy focus on the UK market, compared to global peers like HSBC, leaves it vulnerable to shifts in the domestic economy. A downturn in the housing market or a spike in bad debts could dent profits and put future dividends at risk. And with interest rates potentially falling, the competition for loans might squeeze Lloyds' net interest margin.
The motor finance scandal has somewhat cleared up, but regulatory risks are an ever-present threat in the banking sector, which could impact future payouts.
GSK: Rebounding with a Solid Pipeline
GSK is another strong performer, with its shares nearing a 52-week high at 1,882p. The recent gain of 39.4% is a testament to growing confidence in its medicines pipeline and reduced trade tariff concerns.
New treatments, especially in areas like hepatitis B and vaccines, are strengthening GSK's pipeline, which is crucial for its earnings and future dividends. However, drug development is a complex and unpredictable process. Trials can fail, regulatory approvals are not guaranteed, and GSK faces patent expiries on some existing products later in the decade. If its new medicines don't pan out as expected, both profits and dividend growth could slow, impacting investor payouts.
Valuation and My Verdict
In terms of valuation, Lloyds appears fairly priced rather than cheap. Its price-to-book ratio of 1.3 is in line with HSBC and NatWest, and its dividend yield of 3.3% is similar or slightly below peers. GSK, on the other hand, is yielding around 3.4% with a price-to-earnings ratio of 14.1, which compares favorably to AstraZeneca but remains in line with the broader Footsie average.
My verdict? Lloyds and GSK are classic dividend shares that investors should keep a close eye on in 2026. They offer a combination of regular income, strong share price gains, and clear strategies, albeit in very different industries. However, it's important to remember that nothing is guaranteed in investing. Lloyds' fortunes are tied to the UK economy, and GSK's future depends on its research and development efforts. While I don't think either stock is undervalued based on classic investment metrics, they are solid dividend shares that could add quality and yield to investors' portfolios in 2026.
